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Introduction
The cytochrome P450 2J2 (CYP2J2) epoxygenase is upregulated in a number of cancer types (Jiang et al., 2005) , including breast tumours (Wei et al., 2014) . CYP2J2
converts arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (5, 8, 11, that promote tumourigenesis and tumour cell survival by increasing proliferation and decreasing apoptosis (Chen et al., 2011; Jiang et al., 2007) .
Although the activation of prosurvival signalling pathways has been demonstrated in cells that over-express CYP2J2, or that produce high quantities of EETs , there is less information on the underlying protection mechanisms.
Reactive oxygen species (ROS) have bimodal actions in the regulation of tumour viability. ROS are present in breast tumours (Matsui et al., 2000; Trachootham et al., 2009 ), which promotes cell proliferation and metastatic progression (Nishikawa, 2008) . In contrast, enhanced production of ROS is implicated in tumour cell killing by a range of chemotherapeutic agents (Alexandre et al., 2006; Coriat et al., 2012; Lown, 1985; Mimnaugh et al., 1989) . Mitochondrial electron transport activity is a major site of ROS generation with other potentially important sites including the enzymes xanthine oxidase and NADPH oxidase (Bedard and Krause, 2007; McNally et al., 2003; St Pierre et al., 2002) .
Antioxidant enzymes, such as glutathione peroxide and catalase, and biotransformation enzymes, such as the aldehyde dehydrogenases (ALDHs) and UGT-glucuronosyltransferases (UGTs), are potentially important in protecting cells against ROS and ROS-derived reactive aldehydes that mediate lipid peroxidation (Singh et al., 2013 ).
The present study was undertaken to investigate the mechanism by which CYP2J2 overexpression protects triple-negative MDA-MB-468 breast cancer cells against the cytotoxic chemotherapeutic agent paclitaxel. The principal finding was that expression of ALDH1A1 was markedly enhanced in MDA-2J2 cells and that this enzyme was a major determinant of the efficacy of paclitaxel by conferring protection against ROSmediated cell death.
Materials and methods

Materials
Paclitaxel, doxorubicin, staurosporine, clotrimazole, dimethylsulfoxide (DMSO), 2',7'-dichlorofluorescein diacetate (DCFDA), 2-thiobarbituric acid, 1,1,3,3-tetramethoxypropane, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), malondialdehyde tetrabutylammonium, trans-2-hexenal, PD98059 (ERK inhibitor) the protease inhibitor cocktail and Dulbecco's modified eagle medium (DMEM, containing 1 g glucose/L) were obtained from Sigma-Aldrich (Castle Hill, NSW, Australia). Sorafenib was from Toronto Research Chemicals (Toronto, ON, Canada). Fetal bovine serum was purchased from Thermo Scientific (Scoresby, VIC, Australia) and trypan blue, 0.5% trypsin-EDTA and penicillin-streptomycin (5000 U/mL) were from Life Technologies (Mulgrave, VIC, Australia). Phosphate buffered saline (PBS) was from Amresco (Solon, OH, USA). The ALDH activity assay kit, thiobarbituric acid-reactive substances (TBARs) lipid peroxidation kit, the JC-1 Mitochondrial Membrane Potential Assay Kit, 4-hydroxynonenal (4-HNE), diphenyleneiodonium chloride (DPI), antimycin A1 (antimycin) and allopurinol were purchased from Cayman Chemical (Ann Arbor, MI, USA). SB203580 (p38 mitogenactivated protein kinase; p38 MAP kinase inhibitor), and LY294002 (phosphoinositide 3-kinase/Akt inhibitor) were purchased from Sapphire Biosciences (Waterloo, NSW, Australia).
Murine monoclonal antibodies used to detect human ALDH1A1 and β-actin were from BD Bioscience (cat 611194; Heidelberg, Germany) and Santa Cruz Biotechnology (sc-47778; Santa Cruz, CA), respectively. The mouse monoclonal 4-HNE antibody (MAB3249) and recombinant human ALDH1A1 enzyme were from R&D Systems Inc. (Minneapolis, MN, USA). The rabbit anti-human glyceraldehyde 6-phosphate dehydrogenase antibody (14C10, #2118) was from Cell Signaling Technology (Arundel, QLD, Australia) and the goat anti-mouse secondary antibody (LCR 926-68020) was purchased from Millennium Science (Mulgrave, VIC, Australia).
Cell lines
The and immunoblotting. All cell lines were maintained in DMEM medium containing 10% fetal bovine serum and 100 U/mL penicillin-streptomycin, were cultured at 37 o C in an atmosphere of 5% CO 2 and used between passage 12-20.
Western blotting
Whole cell lysates were prepared in Laemmli sample buffer containing 50 mM dithiothreitol, sonicated for 5 sec (Sonifier 250; Branson Ultrasonics Co., Danbury, CT) and incubated at 95 o C for 5 min. Lysates were electrophoresed on 7.5% sodium dodecyl sulfate-polyacrylamide gels (Murray et al., 1991) , and subjected to western immunoblotting essentially as described previously (Chen et al., 1995 values in the case of paclitaxel were estimated using the sigmoidal, non-linear fit function in Prism (GraphPad Software Inc., La Jolla, CA, USA). Colony formation assays in paclitaxeltreated MDA-MB-231 cells (0.5 µM, 24 h) in soft agar were conducted essentially as described by Franken et al. (2006) .
For the assessment of apoptosis, cells were seeded (1 x 10 4 cells/96-well), allowed to adhere for 24 h and then cultured in serum-free DMEM for 18 h; in some experiments cells were transfected with siRNA as described above. After culture in serum-free DMEM for 18 h, cells were treated with paclitaxel (1 µM) or DMSO (0.05%) for 24 h. Caspase activity was measured using the caspase-Glo 3/7 assay (Promega). For the assay of lipid peroxidation, cells (1 x 10 7 /mL) were suspended in PBS and sonicated on ice at 40 V (3x5 sec intervals; sonifier 250). Lipid peroxidation was measured using a TBARS kit; the standard curve was prepared with 1,1,3,3-tetramethoxypropane.
Briefly, each reaction (1 mL final) contained 100 µl cell lysate, 1% trichloroacetic acid, 29 
Statistical analysis
All data are presented as means ± SEM throughout and were derived from three independent experiments unless otherwise stated. Data from multiple treatments were analysed by one-way ANOVA followed by Tukey's multiple comparison's test. relative to MDA-2J2; Fig 1C) . Fig 2B) .
Results
Over-expression of CYP2J2 protects
Effect of CYP2J2 overexpression on cellular lipid peroxidation
Potential sources of ROS production were assessed in paclitaxel-treated MDA-CTL cells relative to DMSO-treated control (Fig 2C) . The ROS high cell population in DMSOtreated cells was decreased by antimycin, but not allopurinol or DPI. In contrast, the ROS high cell population in paclitaxel-treated cells was decreased by antimycin and DPI, but not allopurinol ( Fig 2C) . These findings suggest that mitochondrial complex activity mediates basal ROS production and that paclitaxel-mediated ROS production involves both mitochondrial complexes and NADPH oxidases. From studies with JC-1, paclitaxeldependent ROS production occurred without any alteration to the mitochondrial membrane potential (not shown).
ALDH1A1 is selectively upregulated in MDA-2J2 cells
To obtain further mechanistic information we examined the expression of genes with potential roles in the modulation of ROS and in cellular protection against paclitaxel. In agreement with our previous microarray findings (Allison et al., 2016) , ALDH1A1 mRNA was strongly upregulated in MDA-2J2 cells (to 227±31 fold of MDA-468; P<0.001; Fig 3A) .
Increased ALDH1A1 function in MDA-2J2 cells relative to both MDA-CTL and MDA-468 cells was confirmed at the levels of protein expression and enzyme activity (Fig 3A) . In contrast, the expression of eight other ALDH genes (ALDHs 1A2, 1A3, 2, 3A1, 3B1, 3B2, 4A1 and 5A1), five UGTs (UGTs 1A1, 1A3, 1A5, 1A6 and 1A8), the ABC transporters MDR1 and MRP1, and the anti-oxidant enzymes catalase and glutathione peroxidase was minimally changed from control (range: 0.61-2.32-fold of MDA-CTL; not shown).
Treatment of MDA-2J2 cells with siRNA directed against CYP2J2 and the CYP2J2 inhibitor clotrimazole both decreased ALDH1A1 immunoreactive protein (Fig 3B) , consistent with a role for CYP2J2-derived EETs in activation of ALDH1A1 expression. We found previously that endogenous EET production was increased in MDA-2J2 cells to ~3.5-fold of that in MDA-CTL (Allison et al., 2016) . In the present study we assessed the role of individual EET regioisomers in the activation of ALDH1A1 expression in MDA-2J2 cells.
As shown in Fig 3C, In comparative studies we evaluated the expression of CYP2J2 and ALDH1A1 in the breast-derived MDA-MB-231, SK-BR-3 and MCF10A lines, lung-derived A549 cells and in prostate-derived PC3 cells. CYP2J2 was detected across the five cell lines, while ALDH1A1 was highly expressed in A549 cells, and at lower level in MDA-MB-231 and SK-BR-3 cells, but was essentially absent from MCF10A and PC3 cells (Fig 3E) . We also evaluated the expression of an alternate ALDH1A isoform -ALDH1A3. Unlike ALDH1A1, ALDH1A3
mRNA was found to be most highly expressed in PC3 cells. There was no apparent relationship between the expression of the two ALDH1A isoforms across the different cell types. Considered together, while not uniform across all of the lines that were tested, coexpression of CYP2J2 and ALDH1A1 was found in cells other than those derived from MDA-MB-468 lines following the stable over-expression of CYP2J2.
ALDH1A1 gene silencing restored the sensitivity of MDA-2J2 cells to paclitaxel
The potential protective role of ALDH1A1 in attenuating the toxicity of paclitaxel in MDA-2J2 cells was evaluated using gene silencing. In initial studies ALDH1A1 knockdown was confirmed at the mRNA (not shown) and protein levels (Fig 4A) . On silencing of ALDH1A1 in MDA-2J2 cells, the anti-proliferative activity of paclitaxel (10 nM -10 µM, 24 h) was restored in MDA-2J2 cells to that in MDA-468 cells (Fig 4B) . Fig 4D) .
The paclitaxel-dependent increase in ROS formation and lipid peroxidation was explored further. We found that paclitaxel increased the formation of 4-HNE-protein adducts in MDA-468 and MDA-CTL cells (to ~1.36±0.04-fold of media alone; P<0.05) and that this was attenuated in MDA-2J2 cells (1.04±0.09-fold of media alone; Fig 4E) . It has been reported that 4-HNE and other reactive aldehydes that are generated following lipid peroxidation are substrates for ALDH1A1 (Xiao et al., 2009) . In the present study we confirmed that recombinant human ALDH1A1 was able to oxidise 4-HNE, malondialdehyde and trans-2-hexenal (not shown). Together, these findings strongly suggest that ALDH1A1
protects MDA-2J2 cells against paclitaxel-mediated ROS production and lipid peroxidation because they detoxify reactive aldehydes that generate protein adducts.
We tested the capacity of additional cytotoxic agents to decrease the viability of (Fig 5B) . We also assessed potential sources of ROS production in MDA-468 cells after treatment with these agents. Similar to findings with paclitaxel, the mitochondrial complex inhibitor antimycin attenuated the doxorubicin-, sorafenib-and staurosporine-dependent increase in ROS high cell populations (P<0.001; Fig 5C) . In addition, the NADPH oxidase inhibitor DPI decreased the ROS high populations in cells that were treated with doxorubicin and sorafenib, but not staurosporine. In summary, the present data indicate that CYP2J2 overexpression in triple-negative MDA-MB-468-derived breast cancer cells upregulated ALDH1A1 and conferred protection against paclitaxel and other agents that activated ROS production from mitochondrial complex III and NADPH oxidases. Paclitaxel is an anti-tubule inhibitor that also increases the production of cytotoxic ROS in target tumour cells (Alexandre et al., 2006; Panis et al., 2012; Ramanathan et al., 2005) . In the present study, rates of basal and paclitaxel-induced lipid peroxidation were lower in MDA-2J2 cells than in MDA-468 or MDA-CTL cells. Basal ROS production was attenuated by the mitochondrial complex III inhibitor antimycin, while antimycin and the NADPH oxidase inhibitor DPI both modulated paclitaxel-mediated ROS production. We also found a pronounced and selective increase in ALDH1A1 expression in MDA-2J2 cells relative to corresponding control cells. In contrast, the expression of eight other ALDH and five UGT enzymes that could also contribute to anti-cancer drug detoxification was minimally altered in MDA-2J2 cells relative to control. In addition, no evidence was obtained for altered expression of the major antioxidant genes catalase and glutathione peroxidase in MDA-2J2 cells, or for increased expression of the ABC-transporters MDR1 and MRP1 that have been associated with anti-cancer drug resistance (Gottesman, 2002) . The present findings support a major role for ALDH1A1 in the protective mechanism of CYP2J2 in MDA-2J2 cells because silencing of ALDH1A1 restored the capacity of paclitaxel to decrease cell viability to levels that were comparable with those in MDA-468 and MDA-CTL cells. In addition, the extent of 4-HNE-mediated protein modification that mediates a decrease in viability was attenuated in MDA-2J2 cells, which is consistent with the capacity of ALDH1A1 to detoxify reactive aldehydes (Xiao et al. 2009 ). Although ALDH1A1 is an established stem cell marker the present findings do not suggest that CYP2J2 over-expression increases the stem cell population in MDA-2J2 cells. Expression of the established breast cancer stem cell markers CD24 and CD44 (Al-Hajj et al., 2003) and members of the ABCtransporter gene family (Gillet et al., 2007) was not increased in MDA-2J2 cells (Allison et al., 2016) .
Discussion
CYP2J2 is over-expressed in breast tumours
In addition to paclitaxel, MDA-2J2 breast cancer cells were resistant to other agents that increased cellular ROS production and decreased cell proliferation, namely doxorubicin, sorafenib and staurosporine. Doxorubicin is known to kill cells via ROS-mediated mechanisms (Friesen et al., 1999; Gouaze et al., 2001 ) and circulating lipid peroxides are elevated in doxorubicin-treated patients (Panis et al., 2012) . ROS production also contributes to the death of breast and liver-derived cells by the multikinase inhibitor sorafenib in vitro and in vivo. Indeed, the extent of sorafenib-mediated ROS formation correlates with the effectiveness of patient treatment (Coriat et al., 2012; Fumarola et al., 2013) . In agreement with the findings with paclitaxel, the sources of doxorubicin-and sorafenib-mediated ROS production were mitochondrial complex III and NADPH oxidases. However, it should be added that it was suggested recently that CYP2J2 could also contribute to the biotransformation of TKIs (Narjoz et al., 2014) ; this possibility cannot be ruled out completely by the present findings. In addition, a role for ROS-mediated cell death by the protein kinase inhibitor staurosporine has been suggested (Kruman et al., 1998) ; this agent targets the mitochondrion and activates the intrinsic pathway of apoptosis (Zhang et al., 2004) . Staurosporine-mediated ROS production was inhibited by the mitochondrial complex III inhibitor antimycin. High levels of ALDH1A1 have been also associated with resistance to other agents that promote ROS-mediated cytotoxicity, including temozolomide in glioblastoma cells (Schafer et al., 2012) , and cyclophosphamide in hematopoietic and pulmonary tumor cells (Magni et al., 1996; Moreb et al., 2005) . In the present study, the sensitivity of cells to paclitaxel was restored by ALDH1A1 knockdown.
The functional role of ALDH1 in tumor biology is incompletely understood but it appears to modulate cell proliferation and survival, and the response to certain oncology drugs (Magni et al., 1996; Moreb et al., 2005) . Over-expression of ALDH1A1 has been shown to confer resistance to chemotherapeutic agents in breast cancer stem cells (Cojoc et al., 2015; Croker and Allan, 2012; Tanei et al., 2009 ). In triple-negative and HER2-positive breast cancers, high level expression of ALDH1A1 has been correlated with metastatic activity and poor prognosis, as well as to the outcome of chemotherapy in patients (Khoury et al., 2012; Liu et al., 2014; Wu et al., 2015) . The present findings are in accord with reports that ALDH1A1 attenuates anti-cancer drug efficacy but now implicate CYP2J2 overexpression, which is a common feature of many human tumors, to increased expression and function of ALDH1A1 (Wei et al., 2014; Jiang et al., 2005) .
The finding that CYP2J2 overexpression in MDA-MB-468 breast cancer cells markedly upregulates ALDH1A1 expression provides new insight into potential treatment strategies in CYP2J2-containing tumors. We found recently that over-expression of CYP2J2
in MDA-MB-468 cells activates EET production (Allison et al., 2016) . In the present study the decrease in ALDH1A1 expression in MDA-2J2 cells after silencing of the CYP2J2 gene or treatment with the CYP2J2 inhibitor clotrimazole implicated CYP2J2-dependent EETs in ALDH1A1 activation. In further studies we found that 14,15-EET activated CYP2J2 expression in MDA-2J2 cells while the regioisomers 8,9-EET and 11,12-EET were inactive.
It was also found that the PI3-kinase/Akt inhibitor LY294002 decreased ALDH1A1 protein expression in MDA-2J2 cells. This finding is compatible with reports that EETs act in part through the PI3-kinase/Akt cascade in cells and implicate that pathway in ALDH1A1 activation in MDA-2J2 cells (Wang et al., 2005; Yang et al., 2007) . Because knockdown of ALDH1A1 in MDA-2J2 cells restored the efficacy of paclitaxel the targeting of ALDH1A1 could be a viable approach for optimizing the efficacy of anti-cancer agents that act in part by ROS generation. There is some evidence that suggests that this approach could be useful.
Agents such as diethylaminobenzaldehyde and disulfiram are established ALDH1 inhibitors that are relatively well tolerated (Koppaka et al., 2012) . Disulfiram resensitized glioma cells to gemcitabine and depleted breast cancer stem cells that express ALDH1A1 (Wang et al., 2014; Liu et al., 2012) and also reportedly induced remission in a patient with stage IV metastatic melanoma (Brar et al. 2004 ).
The present findings support the mechanism proposed in Fig 6. CYP2J2-derived 14,15-EET activates ALDH1A1 expression that protects tumor cells against ROS-dependent lipid peroxidation and reactive aldehyde formation by cytotoxic agents such as paclitaxel.
Reactive aldehydes like 4-HNE generate protein adducts that decrease cell viability; this is attenuated in CYP2J2 cells. While inhibitors of CYP2J2 have been found to decrease the growth of tumours (Chen et al., 2009) , CYP inhibitors often lack selectivity and could elicit clinically significant pharmacokinetic drug interactions by modulating the activity of multiple CYPs (Farrell and Murray, 1990) . In addition, CYP2J2-derived EETs are physiologically important in many extrahepatic tissues (Zeldin, 2001) , which may undermine the strategy of targeting the CYP2J2 enzyme. Instead, approaches in which ALDH1A1 is targeted in adjuvant treatments to be used in combination with cytotoxic agents may be a more refined approach to enhance outcomes from cancer chemotherapy. 
